{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inborn+Errors+of+Metabolism+Disorders&page=55",
    "query": {
      "condition": "Inborn Errors of Metabolism Disorders",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 1513,
    "total_pages": 152,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inborn+Errors+of+Metabolism+Disorders&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inborn+Errors+of+Metabolism+Disorders&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T19:26:36.379Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01963650",
      "title": "Natural History Study of Children With Metachromatic Leukodystrophy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lipid Metabolism Disorders",
        "Metachromatic Leukodystrophy (MLD)",
        "Nervous System Diseases",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Demyelinating Diseases",
        "Metabolism, Inborn Errors",
        "Genetic Diseases, Inborn",
        "Sphingolipidoses",
        "Hereditary Central Nervous System Demyelinating Diseases",
        "Metabolic Inborn Brain Diseases",
        "Lysosomal Storage Diseases",
        "Metabolic Diseases",
        "Sulfatidosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "Up to 12 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-11-02",
      "completion_date": "2016-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 4,
      "location_summary": "Torrance, California • Washington D.C., District of Columbia • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01963650"
    },
    {
      "nct_id": "NCT00002321",
      "title": "A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002321"
    },
    {
      "nct_id": "NCT05253833",
      "title": "Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout",
        "Arthritis, Gouty",
        "Hyperuricemia",
        "Gout Chronic"
      ],
      "interventions": [
        {
          "name": "AR882 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "AR882 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Allopurinol Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arthrosi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-08-12",
      "completion_date": "2024-10-28",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05253833"
    },
    {
      "nct_id": "NCT05845749",
      "title": "Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "MPS IVA",
        "MPS VI"
      ],
      "interventions": [
        {
          "name": "Vosoritide Injection [Voxzogo]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "5 Years to 10 Years"
      },
      "enrollment_count": 6,
      "start_date": "2023-09-25",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05845749"
    },
    {
      "nct_id": "NCT05690204",
      "title": "Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "SAP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanton Pharma Pte. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 87,
      "start_date": "2022-12-12",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • San Diego, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05690204"
    },
    {
      "nct_id": "NCT00829829",
      "title": "PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intercritical Gout"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rilonacept 80 mg",
          "type": "DRUG"
        },
        {
          "name": "Rilonacept 160 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 241,
      "start_date": "2009-02",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829829"
    },
    {
      "nct_id": "NCT01434745",
      "title": "SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Smith-Lemli-Opitz Syndrome"
      ],
      "interventions": [
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Lactose",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "1 Year to 89 Years"
      },
      "enrollment_count": 1,
      "start_date": "2011-09",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434745"
    },
    {
      "nct_id": "NCT02402309",
      "title": "A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjögren-Larsson Syndrome"
      ],
      "interventions": [
        {
          "name": "Active topical NS2 1% dermatologic cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle placebo 0.0% NS2 dermatologic cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-03",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 3,
      "location_summary": "Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02402309"
    },
    {
      "nct_id": "NCT00001521",
      "title": "Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia (CAH)"
      ],
      "interventions": [
        {
          "name": "Fludrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Flutamide",
          "type": "DRUG"
        },
        {
          "name": "Testolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 66,
      "start_date": "1995-06-08",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001521"
    },
    {
      "nct_id": "NCT04833907",
      "title": "rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Canavan Disease"
      ],
      "interventions": [
        {
          "name": "rAAV-Olig001-ASPA",
          "type": "DRUG"
        },
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrtelle Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "60 Months",
        "sex": "ALL",
        "summary": "3 Months to 60 Months"
      },
      "enrollment_count": 24,
      "start_date": "2021-04-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-11-15T19:26:36.379Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04833907"
    }
  ]
}